Last reviewed · How we verify

Nicoletta C Machin — Portfolio Competitive Intelligence Brief

Nicoletta C Machin pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Recombinant Von Willebrand factor Recombinant Von Willebrand factor marketed Recombinant coagulation factor Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site Hematology
IV Iron (standard of care) IV Iron (standard of care) phase 3 Iron replacement therapy Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AMAG Pharmaceuticals, Inc. · 1 shared drug class
  2. AryoGen Pharmed Co. · 1 shared drug class
  3. Baxalta now part of Shire · 1 shared drug class
  4. Medical University of Vienna · 1 shared drug class
  5. NICHD Global Network for Women's and Children's Health · 1 shared drug class
  6. Novo Nordisk A/S · 1 shared drug class
  7. Oregon Health and Science University · 1 shared drug class
  8. Pharmacosmos A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nicoletta C Machin:

Cite this brief

Drug Landscape (2026). Nicoletta C Machin — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nicoletta-c-machin. Accessed 2026-05-16.

Related